150 related articles for article (PubMed ID: 29754833)
1. Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.
Tokuhara H; Imaeda Y; Fukase Y; Iwanaga K; Taya N; Watanabe K; Kanagawa R; Matsuda K; Kajimoto Y; Kusumoto K; Kondo M; Snell G; Behnke CA; Kuroita T
Bioorg Med Chem; 2018 Jul; 26(12):3261-3286. PubMed ID: 29754833
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors.
Mori Y; Ogawa Y; Mochizuki A; Nakamura Y; Fujimoto T; Sugita C; Miyazaki S; Tamaki K; Nagayama T; Nagai Y; Inoue S; Chiba K; Nishi T
Bioorg Med Chem; 2013 Sep; 21(18):5907-22. PubMed ID: 23886807
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.
Imaeda Y; Tawada M; Suzuki S; Tomimoto M; Kondo M; Tarui N; Sanada T; Kanagawa R; Snell G; Behnke CA; Kubo K; Kuroita T
Bioorg Med Chem; 2016 Nov; 24(22):5771-5780. PubMed ID: 27687967
[TBL] [Abstract][Full Text] [Related]
4. A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.
Ostermann N; Ruedisser S; Ehrhardt C; Breitenstein W; Marzinzik A; Jacoby E; Vangrevelinghe E; Ottl J; Klumpp M; Hartwieg JC; Cumin F; Hassiepen U; Trappe J; Sedrani R; Geisse S; Gerhartz B; Richert P; Francotte E; Wagner T; Krömer M; Kosaka T; Webb RL; Rigel DF; Maibaum J; Baeschlin DK
J Med Chem; 2013 Mar; 56(6):2196-206. PubMed ID: 23360239
[TBL] [Abstract][Full Text] [Related]
5. trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.
Lorthiois E; Cumin F; Ehrhardt C; Kosaka T; Sellner H; Ostermann N; Francotte E; Wagner T; Maibaum J
Bioorg Med Chem Lett; 2015 Apr; 25(8):1782-1786. PubMed ID: 25782742
[TBL] [Abstract][Full Text] [Related]
6. The discovery and synthesis of potent zwitterionic inhibitors of renin.
Aspiotis R; Chen A; Cauchon E; Dubé D; Falgueyret JP; Gagné S; Gallant M; Grimm EL; Houle R; Juteau H; Lacombe P; Laliberté S; Lévesque JF; MacDonald D; McKay D; Percival MD; Roy P; Soisson SM; Wu T
Bioorg Med Chem Lett; 2011 Apr; 21(8):2430-6. PubMed ID: 21429746
[TBL] [Abstract][Full Text] [Related]
7. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.
Rahuel J; Rasetti V; Maibaum J; Rüeger H; Göschke R; Cohen NC; Stutz S; Cumin F; Fuhrer W; Wood JM; Grütter MG
Chem Biol; 2000 Jul; 7(7):493-504. PubMed ID: 10903938
[TBL] [Abstract][Full Text] [Related]
8. Optimization of orally bioavailable alkyl amine renin inhibitors.
Xu Z; Cacatian S; Yuan J; Simpson RD; Jia L; Zhao W; Tice CM; Flaherty PT; Guo J; Ishchenko A; Singh SB; Wu Z; McKeever BM; Scott BB; Bukhtiyarov Y; Berbaum J; Mason J; Panemangalore R; Cappiello MG; Bentley R; Doe CP; Harrison RK; McGeehan GM; Dillard LW; Baldwin JJ; Claremon DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):694-9. PubMed ID: 19959358
[TBL] [Abstract][Full Text] [Related]
9. Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.
Chen A; Aspiotis R; Campeau LC; Cauchon E; Chefson A; Ducharme Y; Falgueyret JP; Gagné S; Han Y; Houle R; Laliberté S; Larouche G; Lévesque JF; McKay D; Percival D
Bioorg Med Chem Lett; 2011 Dec; 21(24):7399-404. PubMed ID: 22071301
[TBL] [Abstract][Full Text] [Related]
10. Differences in nonclinical pharmacokinetics between species and prediction of human pharmacokinetics of TAK-272 (SCO-272), a novel orally active renin inhibitor.
Ebihara T; Nishihara M; Takahashi J; Jinno F; Tagawa Y
Biopharm Drug Dispos; 2018 Mar; 39(3):175-183. PubMed ID: 29474740
[TBL] [Abstract][Full Text] [Related]
11. Design and discovery of new (3S,5R)-5-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]piperidine-3-carboxamides as potent renin inhibitors.
Mori Y; Ogawa Y; Mochizuki A; Nakamura Y; Sugita C; Miyazaki S; Tamaki K; Matsui Y; Takahashi M; Nagayama T; Nagai Y; Inoue S; Nishi T
Bioorg Med Chem Lett; 2012 Dec; 22(24):7677-82. PubMed ID: 23122821
[TBL] [Abstract][Full Text] [Related]
12. trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.
Sellner H; Cottens S; Cumin F; Ehrhardt C; Kosaka T; Lorthiois E; Ostermann N; Webb RL; Rigel DF; Wagner T; Maibaum J
Bioorg Med Chem Lett; 2015 Apr; 25(8):1787-1791. PubMed ID: 25754490
[TBL] [Abstract][Full Text] [Related]
13. Novel approach of fragment-based lead discovery applied to renin inhibitors.
Tawada M; Suzuki S; Imaeda Y; Oki H; Snell G; Behnke CA; Kondo M; Tarui N; Tanaka T; Kuroita T; Tomimoto M
Bioorg Med Chem; 2016 Nov; 24(22):6066-6074. PubMed ID: 27720325
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
Atwal KS; O'Neil SV; Ahmad S; Doweyko L; Kirby M; Dorso CR; Chandrasena G; Chen BC; Zhao R; Zahler R
Bioorg Med Chem Lett; 2006 Sep; 16(18):4796-9. PubMed ID: 16870436
[TBL] [Abstract][Full Text] [Related]
15. Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor.
Imaeda Y; Tokuhara H; Fukase Y; Kanagawa R; Kajimoto Y; Kusumoto K; Kondo M; Snell G; Behnke CA; Kuroita T
ACS Med Chem Lett; 2016 Oct; 7(10):933-938. PubMed ID: 27774132
[TBL] [Abstract][Full Text] [Related]
16. Design and optimization of new piperidines as renin inhibitors.
Corminboeuf O; Bezençon O; Grisostomi C; Remeň L; Richard-Bildstein S; Bur D; Prade L; Hess P; Strickner P; Fischli W; Steiner B; Treiber A
Bioorg Med Chem Lett; 2010 Nov; 20(21):6286-90. PubMed ID: 20843686
[TBL] [Abstract][Full Text] [Related]
17. Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition.
Lawhorn BG; Tran T; Hong VS; Morgan LA; Le BT; Harpel MR; Jolivette L; Diaz E; Schwartz B; Gross JW; Tomaszek T; Semus S; Concha N; Smallwood A; Holt DA; Kallander LS
Bioorg Med Chem Lett; 2017 Nov; 27(21):4838-4843. PubMed ID: 28985999
[TBL] [Abstract][Full Text] [Related]
18. The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.
Lorthiois E; Breitenstein W; Cumin F; Ehrhardt C; Francotte E; Jacoby E; Ostermann N; Sellner H; Kosaka T; Webb RL; Rigel DF; Hassiepen U; Richert P; Wagner T; Maibaum J
J Med Chem; 2013 Mar; 56(6):2207-17. PubMed ID: 23425156
[TBL] [Abstract][Full Text] [Related]
19. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
Bezençon O; Bur D; Weller T; Richard-Bildstein S; Remen L; Sifferlen T; Corminboeuf O; Grisostomi C; Boss C; Prade L; Delahaye S; Treiber A; Strickner P; Binkert C; Hess P; Steiner B; Fischli W
J Med Chem; 2009 Jun; 52(12):3689-702. PubMed ID: 19358611
[TBL] [Abstract][Full Text] [Related]
20. Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents.
Lévesque JF; Bleasby K; Chefson A; Chen A; Dubé D; Ducharme Y; Fournier PA; Gagné S; Gallant M; Grimm E; Hafey M; Han Y; Houle R; Lacombe P; Laliberté S; MacDonald D; Mackay B; Papp R; Tschirret-Guth R
Bioorg Med Chem Lett; 2011 Sep; 21(18):5547-51. PubMed ID: 21784634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
